Neuronoff: $4.5 Million Secured For Developing Minimally Invasive Pain Treatments

By Amit Chowdhry • Oct 14, 2025

Neuronoff, a medical device company focused on developing minimally invasive treatments for pain, has closed an oversubscribed financing round, raising $4.5 million.

This funding is expected to propel the company’s Injectrode platform towards obtaining FDA clearance and preparing for its commercial launch. The PNS Injectrode F1 System, the centerpiece of this initiative, is specifically designed for the drug-free treatment of chronic pain.

The funds raised will allow Neuronoff to scale production to 1,000 units annually, paving the way for a limited U.S. launch slated for 2026. The company’s target market includes interventional pain physicians, spinal surgeons, podiatrists, and other healthcare professionals who specialize in managing chronic pain. The Injectrode platform is set to revolutionize pain management by using the smallest implant currently available, measuring just 1mm in diameter—about half the width of a grain of rice.

This device will be delivered through an 18-gauge needle, eliminating the need for the one- to two-inch incisions that are typical in traditional chronic pain neurostimulation therapies. By doing so, the Injectrode aims to provide patients with a minimally invasive and drug-free treatment that avoids surgical incisions, visible scars, and the high costs associated with conventional neuromodulation systems.

Furthermore, Neuronoff is on a mission to significantly reduce healthcare costs for payers, targeting a decrease of 50% or more compared to traditional neuromodulation methods. This cost-saving approach is designed to encourage earlier prior authorization in the treatment process, ultimately enhancing patient access to effective pain management solutions.

The Injectrode has already demonstrated its safety and effectiveness in a first-in-human trial aimed at treating chronic lower back pain. The trial reported no serious adverse events, and the device maintained consistent performance throughout the implantation period. Additionally, the design of the Injectrode platform suggests potential for expansion into various therapeutic areas beyond just pain management.

In a related development, Neuronoff has founded a wholly owned subsidiary dedicated to commercializing the Injectrode platform for an undisclosed medical indication that affects approximately 16 million adults in the US.

KEY QUOTES:

“This funding validates our investors’ confidence in bringing elegant, needle-based neuromodulation to future patients. We aim to offer effective chronic pain treatments without opioids, without surgery, and without scars. Our goal is to provide aesthetically beautiful outcomes, enabling mass market adoption of neuromodulation therapies over the coming years.”

“The Injectrode platform is optimized for CMS lead placement codes that should reduce the probability for peer-to-peer calls for clinicians in the future, broadening treatment access for patients while allowing clinicians to focus on treatments instead of negotiations with insurers. This means more time to treat patients and more patients treated per day. A win for patients, physicians, providers and payers alike.”

Manfred Franke, CEO of Neuronoff

“The neuromodulation sector is prime for an advancement in lead development. Physicians need a better way to deliver these new electrical waveforms to the various anatomical targets.”

Andrew Zeringue, managing member of MedTech Angels